Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

About this update from Sensei Biotherapeutics, Inc.

[{"type":"image","alt":"Sensei Biotherapeutics","displaySize":"","headline":null,"caption":"Sensei Biotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tSVB9mWPe6cbY7LRif6RFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405","width":300,"height":111}},"lazy":false},{"type":"text","content":"- Favorable clinical data in PD-(L)1 resistant patients -","length":57,"tagName":"p"},{"type":"text","content":"- Dose expansion enrollment complete with full data expected by year-end 2025 -","length":79,"tagName":"p"},{"type":"text","content":"- Cash runway into the second quarter of 2026 -","length":47,"tagName":"p"},{"type":"text","content":"BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates.","length":311,"tagName":"p"},{"type":"text","content":"“This was a breakthrough quarter for Sensei,” said John Celebi, President and CEO. “We observed favorable signs of clinical activity in patients with PD-(L)1-resistant cancers from our dose expansion cohort—patients who face poor odds and few options. Beyond the responses we have observed, what’s striking is the emerging potential for prolonged benefit, with some PD-(L)1-resistant patients approaching a year on study. In a population with historically low response rates and fleeting benefit from PD-(L)1 rechallenge, we observed response rates nearly three times higher than what would typically be expected in this setting. With dose expansion enrollment now complete, we’re laser-focused on finalizing a Phase 2 strategy for solnerstotug, guided by the full dataset we plan to present later this year.”","length":809,"tagName":"p"},{"type":"text","content":"Highlights and Milestones","length":25,"tagName":"p"},{"type":"text","content":"Solnerstotug (formerly SNS-101) is a conditionally active antibody designed to selectively target the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation) wi...

More updates from Sensei Biotherapeutics, Inc.